Citations

Clear

1828 citation(s) found for "Su, Emily".

Histone Deacetylase Inhibition Destabilizes the Multi‐Potent State of Uncommitted Adipose‐Derived Mesenchymal Stromal Cells
Dudakovic, Amel , Camilleri, Emily T. , Lewallen, Eric A. , McGee‐Lawrence, Meghan E. , Riester, Scott M. , Montecino, Martı́n , Stein, Gary S., Ryoo, Hyun‐Mo , Dietz, Allan B. , Wijnen, André J. van , Camilleri, Emily , Kakar, Sanjeev , Westendorf, Jennifer J. , van Wijnen, Andre J , Dietz, Allan B , McGee-Lawrence, Meghan E , Camilleri, Emily

Mayo Clinic

Journal of Cellular Physiology | June 9, 2014 | Volume: 230 | Issue: 1 | Pages: 52-62

10.1002/jcp.24680 | PMID 24912092 Get It

Human adipose‐derived mesenchymal stromal cells (AMSCs) grown in platelet lysate are promising agents for therapeutic tissue regeneration. Here, we investigated whether manipulation of epigenetic events by the clinically relevant histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) alters differentiation of AMSCs. The multipotency of AMSCs was validated by their ability to differentiate into osteogenic, chondrogenic, and adipogenic lineages. High‐throughput RNA sequencing and RT‐qPCR established that human histone deacetylases (HDAC1 to HDAC11, and SIRT1 to SIRT7) are differentially expressed in AMSCs. SAHA induces hyper‐acetylation of histone H3 and H4, stimulates protein expression of the HDAC‐responsive gene SLC9A3R1/NHERF1 and modulates the AKT/FOXO1 pathway. Biologically, SAHA interferes with osteogenic, chondrogenic and adipogenic lineage commitment of multipotent AMSCs. Mechanistically, SAHA‐induced loss of differentiation potential of uncommitted AMSCs correlates with multiple changes in the expression of principal transcription factors that control mesenchymal or pluripotent states. We propose that SAHA destabilizes the multi‐potent epigenetic state of uncommitted human AMSCs by hyper‐acetylation and perturbation of key transcription factor pathways. Furthermore, AMSCs grown in platelet lysate may provide a useful biological model for screening of new HDAC inhibitors that control the biological fate of human mesenchymal stromal cells. J. Cell. Physiol. 230: 52–62, 2015. © 2014 Wiley Periodicals, Inc.
High‐Resolution Molecular Validation of Self‐Renewal and Spontaneous Differentiation in Clinical‐Grade Adipose‐Tissue Derived Human Mesenchymal Stem Cells
Dudakovic, Amel , Camilleri, Emily T. , Riester, Scott M. , Lewallen, Eric A. , Kvasha, Sergiy M., Chen, Xiaoyue , Radel, Darcie J., Anderson, Jarett M., Nair, Asha, Evans, Jared M., Krych, Aaron J. , Smith, Jay , Deyle, David R. , Stein, Janet L. , Im, Hee‐Jeong , Cool, Simon M. , Dietz, Allan B. , Wijnen, André J. van , Camilleri, Emily , Stein, Gary S. , Westendorf, Jennifer J. , Kakar, Sanjeev , van Wijnen, Andre J , Krych, Aaron J , Dietz, Allan B , Camilleri, Emily

Mayo Clinic

Journal of Cellular Biochemistry | June 6, 2014 | Volume: 115 | Issue: 10 | Pages: 1816-1828

10.1002/jcb.24852 | PMID 24905804 Get It

AbstractImproving the effectiveness of adipose‐tissue derived human mesenchymal stromal/stem cells (AMSCs) for skeletal therapies requires a detailed characterization of mechanisms supporting cell proliferation and multi‐potency. We investigated the molecular phenotype of AMSCs that were either actively proliferating in platelet lysate or in a basal non‐proliferative state. Flow cytometry combined with high‐throughput RNA sequencing (RNASeq) and RT‐qPCR analyses validate that AMSCs express classic mesenchymal cell surface markers (e.g., CD44, CD73/NT5E, CD90/THY1, and CD105/ENG). Expression of CD90 is selectively elevated at confluence. Self‐renewing AMSCs express a standard cell cycle program that successively mediates DNA replication, chromatin packaging, cyto‐architectural enlargement, and mitotic division. Confluent AMSCs preferentially express genes involved in extracellular matrix (ECM) formation and cellular communication. For example, cell cycle‐related biomarkers (e.g., cyclins E2 and B2, transcription factor E2F1) and histone‐related genes (e.g., H4, HINFP, NPAT) are elevated in proliferating AMSCs, while ECM genes are strongly upregulated (>10‐fold) in quiescent AMSCs. AMSCs also express pluripotency genes (e.g., POU5F1, NANOG, KLF4) and early mesenchymal markers (e.g., NES, ACTA2) consistent with their multipotent phenotype. Strikingly, AMSCs modulate expression of WNT signaling components and switch production of WNT ligands (from WNT5A/WNT5B/WNT7B to WNT2/WNT2B), while upregulating WNT‐related genes (WISP2, SFRP2, and SFRP4). Furthermore, post‐proliferative AMSCs spontaneously express fibroblastic, osteogenic, chondrogenic, and adipogenic biomarkers when maintained in confluent cultures. Our findings validate the biological properties of self‐renewing and multi‐potent AMSCs by providing high‐resolution quality control data that support their clinical versatility. J. Cell. Biochem. 115: 1816–1828, 2014. © 2014 Wiley Periodicals, Inc.
Transvenous Stimulation of the Renal Sympathetic Nerves Increases Systemic Blood Pressure: A Potential New Treatment Option for Neurocardiogenic Syncope
Madhavan, Malini , Ebrille, Elisa , Mulpuru, Siva K. , Mikell, Susan B. , Johnson, Susan B., Suddendorf, Scott H., Ladewig, Dorothy J., Gilles, Emily J., Danielsen, Andrew J., Asirvatham, Samuel J. , DeSimone, Christopher V. , Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 5, 2014 | Volume: 25 | Issue: 10 | Pages: 1115-1118

10.1111/jce.12466 | PMID 24902981 Get It

Renal Vein Stimulation Increases Blood PressureBackgroundNeurocardiogenic syncope (NCS) is a common and sometimes debilitating disorder, with no consistently effective treatment. NCS is due to a combination of bradycardia and vasodilation leading to syncope. Although pacemaker devices have been tried in treating the bradycardic aspect of NCS, no device‐based therapy exists to treat the coexistent vasodilation that occurs. The renal sympathetic innervation has been the target of denervation to treat hypertension. We hypothesized that stimulation of the renal sympathetic nerves can increase blood pressure and counteract vasodilation in NCS.Methods and ResultsHigh‐frequency stimulation (800–900 pps, 10 V, 30–200 seconds) was performed using a quadripolar catheter in the renal vein of 7 dogs and 1 baboon. A significant increase in blood pressure (BP; mean [SD] systolic BP 117 [±28] vs. 128 [±33], diastolic BP 75 [±19] vs. 87 [±29] mmHg) was noted during the stimulation, which returned to baseline after cessation of stimulation. The mean increase in systolic and diastolic BP was 13.0 (±3.3) (P = 0.006) and 10.2 (±4.6) (P = 0.08), respectively.ConclusionWe report the first ever study of feasibility and safety of high‐frequency electrical stimulation of the renal sympathetic innervation to increase BP in animal models. This has potential applications in the treatment of hypotensive states such as NCS.
Preventive Measures for Patients at Risk for Amputation From Diabetes and Peripheral Arterial Disease
Goodney, Philip P. , McClurg, Asha B. , Stone, David H. , DeMartino, Randall R. , Spangler, Emily L. , Brooke, Benjamin S. , Nolan, Brian W.

Mayo Clinic

Diabetes Care | May 22, 2014 | Volume: 37 | Issue: 6 | Pages: e139-e140

10.2337/dc14-0034 | PMID 24855171 Get It

Desulfovibrio legallii Prosthetic Shoulder Joint Infection and Review of Antimicrobial Susceptibility and Clinical Characteristics of Desulfovibrio Infections
Vasoo, Shawn , Mason, Erin L., Gustafson, Daniel R., Cunningham, Scott A. , Cole, Nicolynn C., Vetter, Emily A., Steinmann, Scott P. , Wilson, Walter R., Patel, Robin , Berbari, Elie F. , Henry, Nancy K., Patel, Robin , Cunningham, Scott A

Mayo Clinic

Journal of Clinical Microbiology | May 22, 2014 | Volume: 52 | Issue: 8 | Pages: 3105-3110

10.1128/jcm.00083-14 | PMID 24850351 Get It

ABSTRACT We describe a case of shoulder hemiarthroplasty infection with Desulfovibrio legallii . Antimicrobial susceptibilities of 36 Desulfovibrio isolates are presented. Metronidazole and carbapenems exhibited reliable activity, although piperacillin-tazobactam did not. Eleven previous cases of Desulfovibrio infection are reviewed; most arose from a gastrointestinal tract-related source.
The Incidence of Acute Traumatic Tendon Injuries in the Hand and Wrist: A 10-Year Population-based Study
Jong, Johanna P. de, Nguyen, Jesse T., Sonnema, Anne J. M., Nguyen, Emily C., Amadio, Peter C. , Moran, Steven L. , de Jong, Johanna P

Mayo Clinic

Clinics in Orthopedic Surgery | May 22, 2014 | Volume: 6 | Issue: 2 | Pages: 196

10.4055/cios.2014.6.2.196 | PMID 24900902 Get It

Tibiofemoral alignment in posterior stabilized total knee arthroplasty: Static alignment does not predict dynamic tibial plateau loading
Miller, Emily J. , Pagnano, Mark W. , Kaufman, Kenton R. , Kaufman, Kenton R

Mayo Clinic

Journal of Orthopaedic Research | May 12, 2014 | Volume: 32 | Issue: 8 | Pages: 1068-1074

10.1002/jor.22644 | PMID 24820681 Get It

ABSTRACTFor total knee arthroplasty (TKA), neutral mechanical alignment produces balanced static knee loading. Dynamically, knee loading is affected by more than limb static alignment. We compared static and dynamic knee loading following TKA. Fifteen TKA patients were evaluated pre‐operatively and 2 months and 2 years post‐operatively. Tibiofemoral angles and medial tibial plateau loading were calculated. Pre‐operatively, static medial load was greater for varus than valgus knees. Post‐operatively, no relationship existed between tibiofemoral angle and static medial plateau load. Pre‐operatively and post‐operatively, dynamic medial load was not dependent on tibiofemoral angle. While all patients achieved equal static plateau load distributions at 2 years, only 47% had dynamic medial load distributions of 50 ± 10%. Static tibiofemoral alignment alone does not predict dynamic tibial loading. © 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 32:???–???, 2014.
RUNX3 Facilitates Growth of Ewing Sarcoma Cells
Bledsoe, Krista L., McGee‐Lawrence, Meghan E. , Camilleri, Emily T. , Riester, Scott M. , Wijnen, André J. van , Oliveira, André M. , Camilleri, Emily , Wang, Xiaoke , Westendorf, Jennifer J. , van Wijnen, Andre J , McGee-Lawrence, Meghan E , Camilleri, Emily

Mayo Clinic

Journal of Cellular Physiology | May 8, 2014 | Volume: 229 | Issue: 12 | Pages: 2049-2056

10.1002/jcp.24663 | PMID 24812032 Get It

Ewing sarcoma is an aggressive pediatric small round cell tumor that predominantly occurs in bone. Approximately 85% of Ewing sarcomas harbor the EWS/FLI fusion protein, which arises from a chromosomal translocation, t(11:22)(q24:q12). EWS/FLI interacts with numerous lineage‐essential transcription factors to maintain mesenchymal progenitors in an undifferentiated state. We previously showed that EWS/FLI binds the osteogenic transcription factor RUNX2 and prevents osteoblast differentiation. In this study, we investigated the role of another Runt‐domain protein, RUNX3, in Ewing sarcoma. RUNX3 participates in mesenchymal‐derived bone formation and is a context dependent tumor suppressor and oncogene. RUNX3 was detected in all Ewing sarcoma cells examined, whereas RUNX2 was detected in only 73% of specimens. Like RUNX2, RUNX3 binds to EWS/FLI via its Runt domain. EWS/FLI prevented RUNX3 from activating the transcription of a RUNX‐responsive reporter, p6OSE2. Stable suppression of RUNX3 expression in the Ewing sarcoma cell line A673 delayed colony growth in anchorage independent soft agar assays and reversed expression of EWS/FLI‐responsive genes. These results demonstrate an important role for RUNX3 in Ewing sarcoma. J. Cell. Physiol. 229: 2049–2056, 2014. © 2014 Wiley Periodicals, Inc.
Inhibition Controls for Qualitative Real-Time PCR Assays: Are They Necessary for All Specimen Matrices?
Buckwalter, Seanne P., Sloan, Lynne M., Cunningham, Scott A. , Espy, Mark J., Uhl, J. R., Jones, Mary F. , Vetter, Emily A., Mandrekar, Jayawant N. , Cockerill, Franklin R., Pritt, Bobbi S. , Patel, Robin , Wengenack, Nancy L. , Patel, Robin , Pritt, Bobbi S , Cunningham, Scott A

Mayo Clinic

Journal of Clinical Microbiology | April 16, 2014 | Volume: 52 | Issue: 6 | Pages: 2139-2143

10.1128/jcm.03389-13 | PMID 24740078 Get It

ABSTRACT A retrospective analysis of 386,706 specimens representing a variety of matrix types used in qualitative real-time PCR assays determined the overall inhibition rate to be 0.87% when the inhibition control was added preextraction to 5,613 specimens and 0.01% when the inhibition control was added postextraction but preamplification in 381,093 specimens. Inhibition rates of ≤1% were found for all specimen matrix types except urine and formalin-fixed, paraffin-embedded tissue.
Incidence of chronic lymphocytic leukemia and high‐count monoclonal B‐cell lymphocytosis using the 2008 guidelines
Call, Timothy G. , Hanson, Curtis A. , Achenbach, Sara J., Cerhan, James R. , Rabe, Kari G. , Vachon, Celine M. , Hallberg, Emily J., Norman, Aaron D. , Kay, Neil E. , Zent, Clive S. , Ding, Wei , Vachon, Celine M. , Shanafelt, Tait D. , Slager, Susan L. , Chaffee, Kari G. , Cerhan, James R

Mayo Clinic

Cancer | April 14, 2014 | Volume: 120 | Issue: 13 | Pages: 2000-2005

10.1002/cncr.28690 | PMID 24711224 Get It

BACKGROUNDThe 1996 National Cancer Institute Working Group (NCI‐WG 96) guidelines classified disease in individuals who had a B‐cell clone with chronic lymphocytic leukemia (CLL) immunophenotype as CLL if their absolute lymphocyte count was ≥5 × 109/L. The 2008 International Workshop on CLL guidelines (IWCLL 2008) classified disease as CLL if the absolute B‐cell count was ≥5 × 109/L or as monoclonal B‐cell lymphocytosis (MBL) if the absolute B‐cell count was <5 × 109/L. The objective of the current study of Olmsted County, Minnesota, was to assess the effects of these changes on incidence rates and presentation from 2000 to 2010.METHODSUsing diagnostic indices available through the Rochester Epidemiology Project and the Mayo CLL database, the authors identified all patients with newly diagnosed CLL and high‐count MBL from 2000 to 2010. Age‐specific and sex‐specific incidence rates were determined.RESULTSAccording to NCI‐WG 96 criteria, there were 115 patients with CLL and 8 patients with MBL during the period studied. Using the IWCLL 2008 classification, there were 79 patients with CLL and 40 patients with MBL. Rai stage distribution (low risk, intermediate risk, and high risk) using NCI‐WG 96 criteria was 60.9%, 33.9%, and 5.2%, respectively, compared with 43%, 49.4%, and 7.6%, respectively, using IWCLL 2008 criteria. The age‐adjusted and sex‐adjusted incidence rates (per 100,000) for CLL and MBL were 10.0 and 0.66, respectively, using NCI‐WG 96 criteria versus 6.8 and 3.5, respectively, using IWCLL 2008 criteria. The median time to treatment according to NCI‐WG 96 criteria was 9.2 years versus 6.5 years with IWCLL 2008 criteria.CONCLUSIONSUse of the IWCLL 2008 guidelines reduced the incidence of CLL, altered the distribution of initial Rai stage at diagnosis, and shortened the median time to treatment. Cancer 2014;120:2000–2005. © 2014 American Cancer Society.